Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 46Gastrointestinal 45Lymphoid 39CNS 31Head & Neck 25Thoracic 20Breast 20Gynecologic 18Sarcoma 14Other hematologic neoplasm 13Plasma cell 11Dermatologic 10Endocrine 9Tumor-Agnostic 8Myeloid 8NET 4Other solid neoplasm 3

Conditions

Neuroendocrine Tumors 3Non functioning pancreatic endocrine tumor 1Metastatic Digestive System Neuroendocrine Tumor G1 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 6Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3pembrolizumab 2olaparib 2fludarabine 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Magnetic Resonance Spectroscopy × NET × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT01841736 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡